Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) and Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Risk and Volatility
Abeona Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500.
Insider and Institutional Ownership
80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Abeona Therapeutics and Amylyx Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abeona Therapeutics | $5.82 million | 25.09 | $71.18 million | ($1.07) | -2.39 |
| Amylyx Pharmaceuticals | N/A | N/A | -$144.74 million | ($1.44) | -20.16 |
Abeona Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Abeona Therapeutics and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abeona Therapeutics | -160.30% | -44.82% | -32.51% |
| Amylyx Pharmaceuticals | N/A | -41.54% | -38.91% |
Analyst Recommendations
This is a summary of current ratings and target prices for Abeona Therapeutics and Amylyx Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abeona Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Amylyx Pharmaceuticals | 1 | 0 | 6 | 2 | 3.00 |
Abeona Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 721.92%. Amylyx Pharmaceuticals has a consensus target price of $43.71, suggesting a potential upside of 50.56%. Given Abeona Therapeutics’ higher possible upside, research analysts clearly believe Abeona Therapeutics is more favorable than Amylyx Pharmaceuticals.
About Abeona Therapeutics
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
